Business Context and Reporting Period
This Form 8-K filing by Histogenics Corporation (not Ocugen, Inc.) covers the period ending April 18, 2018, reporting on events occurring on April 16, 2018. The filing focuses on corporate governance changes rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding a specific corporate event and does not contain financial statements.
Material Changes
- Board Expansion: The Board of Directors increased the number of directors from seven to eight.
- Director Appointment: Susan Washer was elected as a Class II director, with her term expiring at the 2019 annual meeting.
- Compensation Structure: Ms. Washer will receive an annual fee of $40,000 and an initial option to purchase 25,000 shares of common stock.
Outlook, Risks, and Management Commentary
The Board determined that Ms. Washer is an independent director in accordance with SEC and Nasdaq rules. She brings significant experience as the President and CEO of Applied Genetic Technologies Corporation (AGTC) since 2002. The filing notes that the Company's amended and restated compensation program for non-employee directors will be detailed in the 2018 proxy statement, expected to be filed in the second quarter of 2018. No specific risks or contingencies related to financial operations were disclosed in this filing.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for additional context on the appointment.
- Review the upcoming 2018 proxy statement for the complete details of the non-employee director compensation program.
- Confirm the vesting schedule of the 25,000 share option granted to Ms. Washer (8.33% every 3 months).
- Check for any potential conflicts of interest given Ms. Washer's current role as CEO of AGTC.